JOP20190186A1 - مركب كينازولين - Google Patents

مركب كينازولين

Info

Publication number
JOP20190186A1
JOP20190186A1 JOP/2019/0186A JOP20190186A JOP20190186A1 JO P20190186 A1 JOP20190186 A1 JO P20190186A1 JO P20190186 A JOP20190186 A JO P20190186A JO P20190186 A1 JOP20190186 A1 JO P20190186A1
Authority
JO
Jordan
Prior art keywords
lung cancer
compound
quinazoline compound
present
pharmaceutical composition
Prior art date
Application number
JOP/2019/0186A
Other languages
English (en)
Inventor
Araki Takanobu
Shimazaki Masashi
Nigawara Takahiro
Kuramoto Kazuyuki
Satake Yoshiki
Yamaki Susumu
Watanabe Kazushi
Kunikawa Shigeki
Shimada Itsuro
Koike Takanori
Abe Tomoaki
Imaizumi Tomoyoshi
Arakawa Keisuke
Akaiwa Michinori
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JOP20190186A1 publication Critical patent/JOP20190186A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

[المشكلة] توفير مركب يكون مفيداً كعنصر نشط خاص بتركيبة صيدلانية لعلاج سرطان الرئة. [وسيلة الحل] عكف القائمون على الاختراع الحالي على دراسة مركب مفيد كعنصر نشط خاص بتركيبة صيدلانية لعلاج سرطان الرئة، ونتيجة لذلك، تبين أن لمركب كينازولين نشاط تثبيطي ممتاز لـKRAS بطفرة G12C، والذي يمكن استخدامه كعامل علاجي لسرطان الرئة، ومن ثم تكون الغاية من الاختراع الحالي قد تم تحقيقها. يمكن استخدام مركب الكينازولين الوارد بالاختراع الحالي وملح منه كعامل علاجي لسرطان الرئة.
JOP/2019/0186A 2017-02-02 2017-06-16 مركب كينازولين JOP20190186A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017017266 2017-02-02
JP2017143607 2017-07-25

Publications (1)

Publication Number Publication Date
JOP20190186A1 true JOP20190186A1 (ar) 2019-08-01

Family

ID=63040813

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0186A JOP20190186A1 (ar) 2017-02-02 2017-06-16 مركب كينازولين

Country Status (21)

Country Link
US (2) US10556906B2 (ar)
EP (1) EP3578560B1 (ar)
JP (1) JP6587116B2 (ar)
KR (1) KR20190113799A (ar)
CN (1) CN110267957B (ar)
AU (1) AU2018216411A1 (ar)
BR (1) BR112019015364A2 (ar)
CA (1) CA3052125A1 (ar)
CO (1) CO2019008487A2 (ar)
ES (1) ES2899871T3 (ar)
IL (1) IL268190A (ar)
JO (1) JOP20190186A1 (ar)
MA (1) MA47433A (ar)
MX (1) MX2019009187A (ar)
PH (1) PH12019501685A1 (ar)
PL (1) PL3578560T3 (ar)
PT (1) PT3578560T (ar)
RU (1) RU2019123529A (ar)
SG (1) SG11201907038WA (ar)
TW (1) TW201838996A (ar)
WO (1) WO2018143315A1 (ar)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
AU2017266911B2 (en) 2016-05-18 2021-09-02 Array Biopharma, Inc. KRas G12C inhibitors
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140600A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused hetero-hetero bicyclic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
TW201900633A (zh) 2017-05-25 2019-01-01 美商亞瑞克西斯製藥公司 Kras之共價抑制劑
EP3630746A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
HUE061599T2 (hu) 2017-11-15 2023-07-28 Mirati Therapeutics Inc KRas G12C inhibotorok
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
JP2021176819A (ja) * 2018-07-31 2021-11-11 アステラス製薬株式会社 キナゾリン化合物を有効成分とする医薬組成物
JP2021176820A (ja) * 2018-07-31 2021-11-11 アステラス製薬株式会社 キナゾリン化合物を有効成分とする医薬組成物
KR20210083286A (ko) * 2018-10-24 2021-07-06 아락세스 파마 엘엘씨 종양 전이를 억제하기 위한 g12c 돌연변이 kras 단백질의 억제제로서 2-(2-아크릴로일-2,6-디아자스피로[3.4]옥탄-6-일)-6-(1h-인다졸-4-일)-벤조니트릴 유도체 및 관련 화합물
US20210395234A1 (en) * 2018-10-26 2021-12-23 Taiho Pharmaceutical Co., Ltd. Novel indazole compound or salt thereof
WO2020113071A1 (en) * 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN111499634B (zh) * 2019-01-31 2023-05-12 贝达药业股份有限公司 一种喹唑啉化合物及其在医药上的应用
EP4249000A3 (en) 2019-02-12 2023-12-27 Novartis AG Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
WO2020177629A1 (zh) * 2019-03-01 2020-09-10 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
WO2020207483A1 (zh) * 2019-04-10 2020-10-15 南京明德新药研发有限公司 一种egfr抑制剂的晶型及其制备方法
CA3137608A1 (en) 2019-04-22 2020-10-29 Betta Pharmaceuticals Co., Ltd Quinazoline compound and pharmaceutical application thereof
MX2021014177A (es) * 2019-05-20 2022-04-25 California Inst Of Techn Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
CN112110918B (zh) * 2019-06-21 2023-08-22 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
CN113993860B (zh) * 2019-06-25 2023-08-01 正大天晴药业集团股份有限公司 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物
CN114222743A (zh) * 2019-08-16 2022-03-22 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物，其制法与医药上的用途
AU2020337938A1 (en) 2019-08-29 2022-03-17 Array Biopharma Inc. KRas G12D inhibitors
EP4034123A4 (en) 2019-09-24 2023-11-01 Mirati Therapeutics, Inc. COMBINATION THERAPIES
JP7340100B2 (ja) 2019-10-28 2023-09-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ ｇ１２ｃ変異型の小分子阻害薬
CA3160142A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
AU2020379734A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
CN112851663B (zh) * 2019-11-12 2023-07-18 博瑞生物医药（苏州）股份有限公司 一种并杂环化合物及其用途
TWI760919B (zh) * 2019-11-15 2022-04-11 大陸商四川海思科製藥有限公司 一種嘧啶並環衍生物及其在醫藥上的應用
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
CN115135315A (zh) 2019-12-20 2022-09-30 米拉蒂治疗股份有限公司 Sos1抑制剂
CA3162106A1 (en) * 2019-12-27 2021-07-01 Yuli Xie Spiro ring-containing quinazoline compound
GB202001344D0 (en) 2020-01-31 2020-03-18 Redx Pharma Plc Ras Inhibitors
WO2021169990A1 (zh) * 2020-02-24 2021-09-02 泰励生物科技（上海）有限公司 用于癌症治疗的kras抑制剂
CN114845997B (zh) * 2020-02-24 2024-03-29 上海喆邺生物科技有限公司 芳香类化合物及其在制备抗肿瘤药物中的应用
CN115335379B (zh) * 2020-03-25 2024-03-29 微境生物医药科技(上海)有限公司 含螺环的喹唑啉化合物
TW202214654A (zh) * 2020-06-10 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 稠合喹唑啉類衍生物、其製備方法及其在醫藥上的應用
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
CN116209438A (zh) 2020-09-03 2023-06-02 锐新医药公司 使用sos1抑制剂治疗具有shp2突变的恶性疾病
CN116457358A (zh) 2020-09-15 2023-07-18 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
WO2022063297A1 (zh) * 2020-09-27 2022-03-31 微境生物医药科技(上海)有限公司 喹唑啉衍生物及其制备方法和用途
US20230365563A1 (en) * 2020-09-30 2023-11-16 Shanghai Pharmaceuticals Holding Co., Ltd. Quinazoline compound and application thereof
WO2022083616A1 (zh) * 2020-10-21 2022-04-28 贝达药业股份有限公司 一种喹唑啉化合物及其药物组合物
CN112341351B (zh) * 2020-10-27 2022-03-11 无锡双启科技有限公司 一种2-氨基-4-溴-3-氟-5-碘苯甲酰胺的制备方法
WO2022105855A1 (en) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
CN115803328A (zh) * 2020-11-24 2023-03-14 成都百裕制药股份有限公司 哌嗪-2,3-二酮衍生物及其在医药上的应用
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022135470A1 (zh) * 2020-12-22 2022-06-30 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022152313A1 (zh) * 2021-01-18 2022-07-21 成都百裕制药股份有限公司 嘧啶衍生物及其在医药上的应用
WO2022171135A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 含螺环的喹唑啉衍生物
WO2022171147A1 (zh) * 2021-02-09 2022-08-18 南京明德新药研发有限公司 嘧啶并芳香环类化合物
AU2022221145A1 (en) * 2021-02-15 2023-09-21 Astellas Pharma Inc. Quinazoline compound for inducing degradation of G12D mutant KRAS protein
KR20230145360A (ko) * 2021-02-15 2023-10-17 아스텔라스세이야쿠 가부시키가이샤 4-아미노퀴나졸린 화합물
CN115124524A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 三环类衍生物及其制备方法和用途
WO2022232318A1 (en) * 2021-04-27 2022-11-03 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
EP4334321A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
CN117813306A (zh) * 2021-05-22 2024-04-02 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物，及其制备和治疗用途
EP4349828A1 (en) * 2021-05-24 2024-04-10 Shanghai Yingli Pharmaceutical Co. Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor and application thereof
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
CA3227706A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022336415A1 (en) 2021-09-01 2024-01-04 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023040989A1 (en) * 2021-09-16 2023-03-23 Suzhou Zanrong Pharma Limited Kras g12c inhibitors and uses thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023122723A1 (en) 2021-12-23 2023-06-29 The Broad Institute, Inc. Panels and methods for diagnosing and treating lung cancer
WO2023119677A1 (en) * 2021-12-24 2023-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising a quinazoline compound
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
TW202346270A (zh) * 2022-03-11 2023-12-01 日商安斯泰來製藥股份有限公司 用於誘發g12d突變kras蛋白分解之雜環化合物
WO2023199180A1 (en) 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024029613A1 (ja) * 2022-08-05 2024-02-08 アステラス製薬株式会社 変異ｋｒａｓタンパクの分解を誘導するための複素環化合物
WO2024034593A1 (ja) * 2022-08-09 2024-02-15 アステラス製薬株式会社 Ｇ１２ｖ変異ｋｒａｓタンパクの分解を誘導するための複素環化合物
WO2024034123A1 (ja) * 2022-08-12 2024-02-15 アステラス製薬株式会社 複素環化合物を含む医薬組成物
GB202212641D0 (en) 2022-08-31 2022-10-12 Jazz Pharmaceuticals Ireland Ltd Novel compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150087628A1 (en) * 2012-04-10 2015-03-26 The Regents Of The University Of California Compositions and methods for treating cancer
WO2015054572A1 (en) * 2013-10-10 2015-04-16 Araxes Pharma Llc Inhibitors of kras g12c
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения

Also Published As

Publication number Publication date
US10556906B2 (en) 2020-02-11
EP3578560B1 (en) 2021-11-10
MX2019009187A (es) 2019-09-26
US20190292182A1 (en) 2019-09-26
JPWO2018143315A1 (ja) 2019-08-08
US20200140437A1 (en) 2020-05-07
SG11201907038WA (en) 2019-08-27
IL268190A (en) 2019-10-31
US10774082B2 (en) 2020-09-15
KR20190113799A (ko) 2019-10-08
TW201838996A (zh) 2018-11-01
ES2899871T3 (es) 2022-03-15
CA3052125A1 (en) 2018-08-09
JP6587116B2 (ja) 2019-10-09
BR112019015364A2 (pt) 2020-03-10
EP3578560A4 (en) 2020-10-21
RU2019123529A (ru) 2021-03-02
CN110267957A (zh) 2019-09-20
WO2018143315A1 (ja) 2018-08-09
MA47433A (fr) 2019-12-11
PL3578560T3 (pl) 2022-01-17
EP3578560A1 (en) 2019-12-11
PT3578560T (pt) 2021-12-13
CN110267957B (zh) 2022-04-26
PH12019501685A1 (en) 2020-06-01
CO2019008487A2 (es) 2019-08-20
AU2018216411A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
JOP20190186A1 (ar) مركب كينازولين
PH12018501920B1 (en) Bromodomain inhibitors
PH12016501750A1 (en) Human plasma kallikrein inhibitors
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2023002507A (es) Inhibidores de cd73.
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
NZ788133A (en) Cd73 inhibitors
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
PH12017500436A1 (en) Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
PH12017501668A1 (en) Bace1 inhibitors
MX2019004187A (es) Inhibidores de bromodominios.
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
MX2019001210A (es) Composicion farmaceutica anticancer.
EA201991630A1 (ru) Соединение хиназолина
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
MX2019014773A (es) Inhibidores de ccl2.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
EA202091668A3 (ru) Ингибиторы калликреина плазмы человека